Medical/Pharmaceuticals Global News & Press Release Distribution

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...

2023-11-07 20:00 2908

First Mover of Global Trade Index Based On Biome Molecule, Kwanyoung Park of AndKwan Natural Science

* Creating world-class innovation by redefining how international standards are established with eco-friendly bio materials and a system. * Patent registration for one-stop system from procurement of raw materials and golden time orders from all over the world to search for optimal routes for ...

2023-11-07 15:47 3008

First Mover of Global Trade Index Based On Biome Molecule, Kwanyoung Park of AndKwan Natural Science

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malign...

2023-11-07 14:14 2350

87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...

2023-11-07 12:31 2817

AIRS Medical inks partnership agreement with FONAR Corporation, leveraging the experience of the pioneering company in MRI... Success cases to be presented at RSNA 2023

SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- AIRS Medical, the leading AI-powered healthcare solution provider, recently announced a strategic partnership with FONAR Corporation (NASDAQ:FONR), the pioneer company in the MRI industry, to accelerate and develop business inNorth America. AIRS M...

2023-11-07 00:00 2733

Lerna Bio unveils its first-in-class solution to combat liver failure

SINGAPORE, CAMBRIDGE, Mass. and SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Lerna Biopharma Pte. Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting inBoston organized by American Association for the Study of Liver Diseases (AA...

2023-11-06 22:00 2449

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies...

2023-11-06 21:00 2276

Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023

* Two oral presentations and five ePosters accepted by the RSNA: presenting AI advancements for chest radiograph reporting efficiency and breast cancer risk assessment SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer ...

2023-11-06 21:00 2670

Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Jolly Good to hold VR Seminar at GSA 2023, Gerontological Society of America! TOKYO, Nov. 6, 2023 /PRNewswire/ -- Jolly Good US Inc. (Brookline, Massachusetts, USA CEO: Kensuke Joji), a developer of medical VR, is pleased to announce that it has developed the first "Palliative Care Communication ...

2023-11-06 21:00 2575

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeting (abstract #2536 & #e13091) and ESMO Congress (abstract #1992P) BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China ZHUHAI, China, Nov. 6...

2023-11-06 20:00 4044

The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval

YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...

2023-11-06 09:11 2350

Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy

SHANGHAI, Nov. 4, 2023 /PRNewswire/ -- On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The KGX101 clin...

2023-11-05 08:00 3353

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao,Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, indust...

2023-11-03 12:10 1550

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaft...

2023-11-03 09:15 1728

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the ...

2023-11-03 09:10 1583

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...

2023-11-03 05:15 1235

Complete Genomics and Basepair™ Announce Technology Integration Partnership

SAN JOSE, Calif. and NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Complete Genomics and Basepair, Inc today announced a technology integration partnership to accelerate the analysis and interpretation of genomic data generated by Complete Genomics' DNBSEQTM sequencing platforms*. The partnership gives ...

2023-11-02 21:00 2347

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio * I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myelom...

2023-11-02 20:00 2022

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...

2023-11-02 20:00 1698

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") thro...

2023-11-02 15:58 2627